1. Home
  2. PRPL vs KPTI Comparison

PRPL vs KPTI Comparison

Compare PRPL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

HOLD

Current Price

$0.72

Market Cap

89.8M

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$7.26

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPL
KPTI
Founded
2010
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.8M
94.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
PRPL
KPTI
Price
$0.72
$7.26
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$1.00
$22.17
AVG Volume (30 Days)
225.0K
224.8K
Earning Date
11-04-2025
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$457,012,000.00
$142,530,000.00
Revenue This Year
N/A
$3.82
Revenue Next Year
$12.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$3.51
52 Week High
$1.29
$12.45

Technical Indicators

Market Signals
Indicator
PRPL
KPTI
Relative Strength Index (RSI) 42.89 62.21
Support Level $0.70 $7.12
Resistance Level $0.78 $7.70
Average True Range (ATR) 0.04 0.53
MACD -0.01 0.08
Stochastic Oscillator 17.73 74.27

Price Performance

Historical Comparison
PRPL
KPTI

About PRPL Purple Innovation Inc.

Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: